Wegovy isn’t inherently bad for you, but it carries real risks that range from common nuisances to rare serious events. For most people who use it as prescribed, the benefits of significant weight loss and reduced cardiovascular risk outweigh those risks. The more useful question is whether the specific risks apply to your body and your medical history.
The Most Common Side Effects
Nausea is the side effect most people experience first, and it’s the reason Wegovy uses a slow dose-escalation schedule over roughly 16 weeks. You start at a very low dose (0.25 mg weekly) and increase every four weeks until reaching the maintenance dose. This gradual ramp-up exists specifically to let your gut adjust. If a particular dose increase hits you hard, your prescriber can hold at that level for an extra four weeks before moving up again.
Beyond nausea, the most frequently reported gastrointestinal issues include vomiting, diarrhea, constipation, and stomach pain. These tend to peak during dose increases and fade over time. For some people they remain mild and manageable. For others, they’re severe enough to quit treatment entirely. The drug works partly by slowing how fast your stomach empties, which is why the gut bears the brunt of the adjustment.
Serious Gastrointestinal Risks
A study published in JAMA examined insurance claims data and found that semaglutide users had an incidence rate of about 9 cases of gastroparesis per 1,000 person-years. Gastroparesis is a condition where the stomach empties abnormally slowly, causing persistent nausea, vomiting, bloating, and pain that goes beyond typical side effects. Pancreatitis, an inflammation of the pancreas that can become a medical emergency, occurred at a rate of roughly 5 cases per 1,000 person-years. Bowel obstruction, often raised as a concern, showed zero cases in that dataset.
These numbers mean the absolute risk for any individual is low, but they aren’t negligible. If you develop severe, persistent abdominal pain (especially pain that radiates to your back), that warrants immediate medical attention because it could signal pancreatitis.
The Thyroid Cancer Warning
Wegovy carries the FDA’s most serious label warning, a boxed warning, about thyroid tumors. In animal studies, semaglutide caused dose-dependent tumors in the thyroid’s C-cells, the cells that can give rise to medullary thyroid carcinoma (MTC). The critical caveat: it remains unknown whether this happens in humans. The rodent thyroid cells that developed tumors respond to this class of drug differently than human cells do.
Still, the uncertainty is enough that Wegovy is flatly contraindicated if you have a personal or family history of MTC, or if you have a genetic condition called Multiple Endocrine Neoplasia syndrome type 2. These aren’t soft recommendations. If either applies to you, this drug is off the table. For everyone else, symptoms worth watching for include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
A Possible Link to Vision Problems
A newer area of concern involves a rare condition called ischemic optic neuropathy, sometimes described as an “eye stroke.” Research has found that Wegovy, specifically at its higher maintenance dose, showed a stronger association with this condition than lower-dose semaglutide formulations used for diabetes. The leading theory is that rapid weight loss, fluid shifts, and drops in blood pressure (particularly overnight) may reduce blood flow to the optic nerve. Men appeared to be at higher risk. This is still a rare event, but it’s worth knowing about, particularly if you already have risk factors for vascular eye conditions.
Cardiovascular Benefits
The risk picture isn’t one-sided. The SELECT trial, one of the largest cardiovascular outcome studies conducted with a weight-loss drug, found that semaglutide at Wegovy’s dose reduced major adverse cardiovascular events by 20% compared to placebo. This included heart attacks, strokes, and cardiovascular death in people who already had established heart disease and were overweight or obese. That result was significant enough that the FDA approved Wegovy specifically for reducing cardiovascular risk in that population.
This is a meaningful benefit. Obesity itself is a driver of heart disease, high blood pressure, sleep apnea, type 2 diabetes, and joint degeneration. For people with substantial weight to lose, the cardiovascular protection from Wegovy may offset several of the drug’s risks. The calculus is different for someone seeking to lose 10 or 15 vanity pounds versus someone with a BMI over 35 and existing metabolic disease.
What Happens When You Stop
One of the most important things to understand about Wegovy is that it works while you take it. A 2025 systematic review in The BMJ estimated that people regain an average of about 10 kilograms (roughly 22 pounds) within the first year after stopping newer, more potent incretin drugs like semaglutide. That works out to approximately 0.8 kg (about 1.7 pounds) per month of steady regain.
This doesn’t mean the drug “failed.” It means obesity, for many people, is a chronic condition that requires ongoing treatment, much like blood pressure medication controls hypertension without curing it. But it does change the risk calculation. If you’re weighing whether Wegovy is “bad” for you, factor in that you may need to stay on it long-term to maintain results, which means long-term exposure to its side effects and costs.
Who Should Not Take Wegovy
The FDA lists two absolute contraindications: a personal or family history of medullary thyroid carcinoma or MEN 2, and a prior serious allergic reaction to semaglutide or any ingredient in the formulation. Beyond those hard stops, prescribers typically exercise caution with people who have a history of pancreatitis, severe gastrointestinal disease, or significant kidney problems.
Wegovy also isn’t designed for use alongside other semaglutide products (like Ozempic) or other GLP-1 receptor agonists. Stacking these drugs doesn’t improve results and increases the risk of serious side effects.
Weighing the Trade-Offs
For someone with obesity-related health problems, Wegovy offers clinically proven weight loss averaging 15% of body weight and a 20% reduction in cardiovascular events. Those are substantial, life-altering benefits. The trade-offs are persistent GI discomfort for many users, small but real risks of pancreatitis and gastroparesis, an unresolved question about thyroid tumors, a rare link to vision problems, and the reality that stopping the drug typically means regaining most of the weight.
Whether that equation tips toward “worth it” or “not worth it” depends entirely on your starting point. For someone at high cardiovascular risk carrying significant excess weight, the benefits are hard to argue with. For someone closer to a normal weight range with no metabolic complications, the risk-benefit balance shifts considerably. The drug itself isn’t categorically bad or good. It’s a powerful tool with real costs, and understanding both sides is what lets you make a clear-eyed decision.